NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
75 trialsNCT03170206 2026-02-12
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT02668666 2026-01-20
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02630693 2025-11-25
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT02297438 2025-10-27
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT01907607 2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2 Completed
NCT02730429 2025-07-31
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT01356628 2025-07-28
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Thomas Jefferson University
Phase 2 Completed
NCT03844997 2025-05-31
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03472573 2025-05-15
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Thomas Jefferson University
Phase 1 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05178888 2025-02-11
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Mirati Therapeutics Inc.
Phase 1 Completed
NCT03854903 2025-02-06
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
Georgetown University
Phase 1 Completed
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02491983 2024-12-09
PARSIFAL
MedSIR
Phase 2 Completed
NCT02530320 2024-11-22
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT03238196 2024-11-14
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT03526250 2024-11-01
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02389842 2024-09-26
PIPA
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02913430 2024-09-23
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
University of Pittsburgh
Phase EARLY_PHASE1 Completed
NCT03981614 2024-08-22
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT03560531 2024-08-09
A Study of ZN-c5 in Subjects With Breast Cancer
Zeno Alpha Inc.
Phase 1/2 Completed
NCT02599714 2024-06-06
PASTOR
AstraZeneca
Phase 1 Completed
NCT02448420 2024-04-18
PATRICIA II
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT03007979 2024-03-20
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02022982 2024-03-19
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02536742 2024-02-26
PYTHIA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03936270 2024-02-20
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT02101034 2023-12-21
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Washington University School of Medicine
Phase 1/2 Completed
NCT01864746 2023-12-12
PENELOPE-B
GBG Forschungs GmbH
Phase 3 Completed
NCT03054363 2023-11-13
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
University of Colorado, Denver
Phase 1/2 Completed
NCT02897375 2023-10-10
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
Phase 1 Completed
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT02499120 2023-09-08
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Pfizer
Phase 2 Completed
NCT03809988 2023-09-07
PALMIRA
MedSIR
Phase 2 Completed
NCT03065621 2023-04-19
NeoRHEA
Jules Bordet Institute
Phase 2 Completed
NCT03110744 2023-03-27
NCT-PMO-1601
University Hospital Heidelberg
Phase 2 Completed
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT03447132 2023-03-10
SAFIA
International Cancer Research Group, United Arab Emirates
Phase 3 Completed
NCT03455270 2022-12-15
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
G1 Therapeutics, Inc.
Phase 1 Completed
NCT02448771 2022-10-24
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02806050 2022-10-12
Palbociclib and FES PET
University Medical Center Groningen
Phase 2 Completed
NCT03965845 2022-09-19
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Completed
NCT02871791 2022-08-29
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
Phase 1/2 Completed